A randomized phase III study of abemaciclib versus erlotinib in patients with stage IV non-small cell lung cancer with a detectable KRAS mutation who failed prior platinum-based therapy: JUNIPER - Goldman, Jonathan W.; Mazieres, Julien; Barlesi, Fabrice; Dragnev, Konstantin H.; Koczywas, Marianna; Göskel, Tuncay; Cortot, Alexis B.; Girard, Nicolas; Wesseler, Claas; Bischoff, Helge; Nadal, Ernest; Park, Keunchil; et al. (Frontiers in oncology, 2020)
Gesehen am 19.04.2021